@Nasdaq helped us in celebrating our Series B with a billboard in the heart of Time Square! Thank you to our friends at Nasdaq for your support on our mission to create cures for patients!

For Cancer Immunotherapy Awareness Month, Strands participated in today's #WearWhite campaign honoring the dedication of patients, caregivers, and researchers working to improve cancer treatment

This is the standard our co-founder and CEO, @DrSynbio, holds Strand to – and it’s the lens through which our team thinks about everything from how we design drugs to how we push for the regulatory reform that gets treatments to patients faster. Jake joined @tferriss to talk through the science, the clinical results, and what it will actually take to make that goal a reality. Listen here: tim.blog/2026/06/02/jake-bec…

What if off-target effects weren’t a delivery problem but a programming problem? Our programmable mRNA platform uses molecular sensors to make sure only tumor cells can “read” the message and produce the protein that triggers their destruction. Healthy cells ignore the mRNA altogether. @GENbio featured our approach in their recent piece on next-gen therapeutic modalities: genengnews.com/topics/drug-d…

"We are standing right now on the precipice of a revolution in genetic medicine." Strand CEO @DrSynbio on @tferriss' podcast. Full episode: podcasts.apple.com/us/podcas…

What if a medicine could decide when and where to activate inside your body? Strand co-founder and CEO @DrSynbio joined the @ProgressPotent1 podcast with @irat1onal to discuss programmable mRNA therapeutics, Strand’s origins at MIT, and what early clinical results mean for the future of genetic medicine. Listen here: podcasts.apple.com/us/podcas…

Thursday morning, our Chief Medical Officer @jasonlukemd joins leaders from @IN8bio, @MedicalCollege, and @advarra for a @FiercePharma webinar on translating cutting-edge oncology science into operationally executable trials. The conversation will cover adaptive trial design, patient access, and what it actually takes to run next-generation oncology studies at scale. 🔬Don't miss it! Register at the link below. fiercepharma.com/premium/web…

mRNA therapeutics are a powerful modality. It's also one where you can’t take shortcuts if you want to succeed, and circular RNA (circRNA) is no different. In a new interview with @PharmaScrip’s @awmcconaghie, our co-founder, President, and Head of R&D @tasuku_kitada breaks down what it takes to build an in vivo CAR-T platform that can deliver in the clinic: optimized circRNA architecture, targeted lipid nanoparticle (LNP) delivery, and programmable safety controls built directly into the construct. With major pharma bets pouring into the space, Tasuku makes the case that the companies that win will be the ones that did the engineering work before rushing to the clinic. Read more: insights.citeline.com/scrip/…

Circular RNA is emerging as one of the most exciting frontiers in gene and cell therapy. At Strand, we've been building on it for years. BioWorld's @MarJungle covered the latest advances at #ASGCT2026, including a conversation with our co-founder, President, and Head of R&D @tasuku_kitada. They discuss how Strand is using circRNA to power STX-005, our in vivo CAR-T program designed to be a redosable, off-the-shelf approach to cell therapy. Read more: bioworld.com/articles/731268…

Strand stays committed to fostering the next generation of scientists. Shoutout to Strands Eloise, Gautam and Daniel for participating as judges for the MSEF Middle School Science Fair this past weekend!

Programmable RNA is coming for in vivo CAR-T. Tomorrow at #ASGCT2026, our Principal Scientist Ashlesha Odak, Ph.D. is presenting preclinical NHP data showing how programmable circRNA, combined with a targeted LNP approach, can generate functional CAR-T cells in vivo with integrated safety controls. No cell extraction, no manufacturing facility. This is pioneering what's possible in programmable genetic medicine. Watch the presentation to find out for yourself: 📢 LNPs for in vivo CAR-T applications 📅 Tuesday, May 12, at 9:00-9:15 am ET 📍 MCEC Room 210 ABC (Level 2) Presentation abstract can be found here: annualmeeting.asgct.org/abst…

Our CEO @DrSynbio sat down with @FierceBiotech’s @Angus_Fierce to talk about the regulatory and manufacturing barriers slowing first-in-human clinical trials in the U.S., and what a more efficient pathway to first-in-human trials could mean for American patients. Read the conversation here: fiercebiotech.com/biotech/co…

Strand Therapeutics is heading to the @MilkenInstitute Global Conference 2026 in Los Angeles. On May 4 at 10 a.m. PT, our CEO and co-founder, @DrSynbio, will join an invitation-only panel on sustaining American leadership in biomedical innovation. He’ll be joined by @SecAzar, 24th U.S. Secretary of Health and Human Services; @mmrozenman, CFO and CBO of @insitro; and @rtnarch, co-founder and managing director of ARCH Venture Partners. The session will be moderated by @SungHeeTweets, managing director of FasterCures at Milken Institute Health. Looking forward to continuing the conversation at #MIGlobal. milkeninstitute.org/content-…

We're excited to welcome Kunal Bhatia to Strand as Chief Financial Officer. Kunal brings 15 years of investment banking experience advising biopharmaceutical companies on financing and business development, most recently as interim CFO and CBO to a portfolio of life sciences companies. His appointment comes as Strand advances a growing pipeline – STX-001 clinical data, STX-003 heading to the clinic in mid-2026, and our in vivo CAR-T program – and builds on a $153M Series B. As we enter this next chapter, Kunal's expertise in capital formation and strategic partnerships positions Strand to keep advancing our mission of integrating programmable genetic medicines into the core of modern therapeutics. Read more: businesswire.com/news/home/2…

Generating CAR-T cells inside the body, without removing and reengineering a patient's cells, has long been one of cell therapy's most persistent unsolved challenges. We're presenting data at #ASGCT2026 with data that shows how programmable mRNA can deliver on it. Ashlesha Odak, PhD will go over preclinical findings from the circRNA-LNP platform showing near-complete B cell depletion in non-human primates following IV dosing, with programmable safety controls built in. Presentation details below. Full abstract here: annualmeeting.asgct.org/abst… Abstract Title: Programmable circRNA-tLNP platform enables efficient in vivo CAR-T cell programming and robust activity in a NHP model Session Type: Oral Session Name: LNPs for in vivo CAR-T applications Date and Time: Tuesday, May 12, 2026, at 9:00-9:15 am ET Location: MCEC Room 210 ABC (Level 2)